DERM Dermira, Inc.

30.39
+0  (0%)
Previous Close 30.39
Open 29.48
Price To book 4.31
Market Cap 1.08B
Shares 35,603,000
Volume 381,559
Short Ratio 9.90
Av. Daily Volume 212,792

SEC filingsSee all SEC filings

  1. 8-K/A [Amend] - Current report 17505570
  2. 8-K - Current report 162072778
  3. CT ORDER - Confidential treatment order 162066414
  4. SC 13G - Statement of acquisition of beneficial ownership by individuals 162064352
  5. 8-K - Current report 161978619

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data from first trial released October 2016 - endpoints met. Second trial data released December 8, 2016 - endpoints met. Data from third trial due 1Q 2017.
Cimzia
Moderate-to-severe plaque psoriasis
Phase 3 trial initiation announced January 3, 2017. Data are due 1H 2018.
Olumacostat glasaretil (DRM01)
Acne
Phase 3 data released June 2016. NDA Filing 2H 2017.
DRM04
Primary axillary hyperhidrosis

Latest News

  1. Dermira Provides Corporate Update
  2. Dermira Provides Corporate Update
  3. Dermira, Inc. breached its 50 day moving average in a Bullish Manner : DERM-US : January 5, 2017
  4. Lori Lyons-Williams Joins Dermira as Chief Commercial Officer
  5. Lori Lyons-Williams Joins Dermira as Chief Commercial Officer
  6. Dermira Elects Emmanuel Caeymaex to Board of Directors
  7. DERMIRA, INC. Files SEC form 8-K/A, Change in Directors or Principal Officers
  8. Dermira Elects Emmanuel Caeymaex to Board of Directors
  9. Dermira Initiates Phase 3 Clinical Program in Acne
  10. Dermira Initiates Phase 3 Clinical Program in Acne
  11. ETFs with exposure to Dermira, Inc. : December 29, 2016
  12. DERMIRA, INC. Files SEC form 8-K, Change in Directors or Principal Officers
  13. ETFs with exposure to Dermira, Inc. : December 9, 2016
  14. Dermira, Inc. :DERM-US: Earnings Analysis: Q3, 2016 By the Numbers : December 8, 2016
  15. Second CIMZIA® (certolizumab pegol) Phase 3 Trial Meets Co-primary Efficacy Endpoints in Patients with Moderate-to-Severe Chronic Plaque Psoriasis
  16. Is Merit Medical Systems, Inc. (MMSI) A Good Stock To Buy?
  17. Is Bottomline Technologies (EPAY) A Good Stock To Buy?
  18. Dermira, Inc. breached its 50 day moving average in a Bearish Manner : DERM-US : November 23, 2016
  19. DERMIRA, INC. Financials
  20. Dermira, Inc. breached its 50 day moving average in a Bullish Manner : DERM-US : November 11, 2016

SEC Filings

  1. 8-K/A [Amend] - Current report 17505570
  2. 8-K - Current report 162072778
  3. CT ORDER - Confidential treatment order 162066414
  4. SC 13G - Statement of acquisition of beneficial ownership by individuals 162064352
  5. 8-K - Current report 161978619
  6. 10-Q - Quarterly report [Sections 13 or 15(d)] 161978063
  7. 8-K - Current report 161898145
  8. D - Notice of Exempt Offering of Securities 161881212
  9. 8-K - Current report 161814396
  10. 10-Q - Quarterly report [Sections 13 or 15(d)] 161814169